



Practitioner's Docket No. 2002DE121

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Schlosser, et al.

Application No.: 10/625,281
Filed: 7/23/2003
For: Flame Retardant Combination

Group No.:

Commissioner for Patent
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

CERTIFICATION UNDER 37 C.F.R. Sections 1.8(a) and 1.10*
*(When using Express Mail, the Express Mail label number is **mandatory**;
Express Mail certification is optional.)*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

☒ deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. section 1.8(a)

37 C.F.R. section 1.10*

☒ with sufficient postage as first class mail.

☐ as "Express Mail Post Office to Address"
Mailing Label No. _____ (**mandatory**)

TRANSMISSION

☐ transmitted by facsimile to the Patent and Trademark Office (703) _____.

Date: 12/10/2003

Ricki D. Barley
Signature

Ricki D. Barley
(type or print name of person certifying)

***WARNING:** Each paper or fee filed by "Express Mail" **must** have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b).
"Since the filing of correspondence under [section] 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will **not** be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.


Dear Sir:

In accordance with the duty of disclosure provisions of 37 CFR §1.56, there is hereby provided certain information which the Examiner may consider material to the examination of the subject U.S. patent application. It is requested that the Examiner make this information of record if it is deemed material to the examination of the subject application. No admission is made that the information cited in this Statement is, or is considered to be, material to patentability nor a representation that a search has been made (other than search report(s) from a counterpart foreign application or a PCT International Search Report, if submitted herewith).

1. ☒ Enclosures accompanying this Information Disclosure Statement are:
 - 1a. ☒ Form PTO-1449.
 - 1b. ☒ Copies of Information Disclosure Statement citations.
 - 1c. ☐ PCT Search Report
 - 1d. ☒ Copies of Co-pending U.S. Applications.
2. ☐ This Information Disclosure Statement is filed under 37 CFR §1.97(b) with the filing of the U.S. patent application. Accordingly, no fee or §1.97(e) Statement is required.
3. ☒ This Information Disclosure Statement is filed under 37 CFR §1.97(b) before the latter of three months after the U.S. patent application filing date or the first Office Action on the merits. Accordingly, no fee or §1.97(e) Statement is required.
4. ☐ This Information Disclosure Statement is filed under 37 CFR §1.97(c) after the first Office Action on the merits, but before a Final Office Action or a Notice of Allowance. The \$180.00 fee set forth in 37 CFR §1.17(p) in accordance with 37 CFR §1.97(c) is to be charged to Deposit Account No. 03-2060.
5. ☐ This Information Disclosure Statement is filed under 37 CFR §1.97(e) in that each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Accordingly, no fee is required.
6. ☐ This Information Disclosure Statement is filed in conjunction with a Request For Continued Examination. Accordingly, no fee or §1.97(e) Statement is required.

7. ☒ The English language documents identified by reference in the TRANSLATION Section of the foreign patents list of the attached 1449 Form are believed to be a concise statement, or the equivalent or substantial equivalent to the foreign language documents cited in the attached 1449 Form.
8. ☒ In addition to the documents cited, the Office's attention is directed to the following co-pending U.S. Application Serial Number(s), copies of which are attached for the convenience of the Office:
- a. U.S. serial no. 10/669,483, filed 9/24/2003, Sicken, et al.
 - b. U.S. serial no. 10/669,921, filed 9/24/2003, Sicken, et al.
 - c. U.S. serial no. 10/669,973, filed 9/24/2003, Sicken, et al.

Respectfully submitted,




Anthony A. Bisulca

Registration No. 40,913

CUSTOMER NO. 25,255

Clariant Corporation
Industrial Property Department
4000 Monroe Road
Charlotte, North Carolina 28205
Telephone: 704/331-7151
Facsimile: 704/331-7707

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (37 CFR 1.98(b))				ATTY. DOCKET NO. 2002DE121		SERIAL NO. 10/625,281	
				APPLICANT: Schlosser, et al.			
				FILING DATE: 7/23/03		GROUP:	
FOREIGN PATENT OR PUBLISHED FOREIGN APPLICATION							
		DOCUMENT NUMBER	PUB. DATE	COUNTRY			TRANSLATION
✓	BA	DE 2 252 258	5/9/74	Germany			See AA Above
✓	BB	DE 24 47 727	4/8/76	Germany			See AB Above
✓	BC	EP 0 584 567	3/2/94	Europe			See AE Above
✓	BD	EP 0 699 708	3/6/96	Europe			See CA Below
✓	BE	WO 97/39053	10/23/97	WIPO			See AJ Above
✓	BF	WO 97/44377	11/27/97	WIPO			English
✓	BG	DE 197 34 437	2/11/99	Germany			See AF Above
✓	BH	DE 197 37 727	7/8/99	Germany			See AM Above
✓	BI	WO 00/02869	1/20/00	WIPO			English
✓	BJ	EP 0 990 652	4/5/00	Europe			English
	BK						

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication**)

	CA	English abstract for EP 0699708, 3/6/1996
	CB	
EXAMINER		DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

Examiner Initial		Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	3,900,444	8/19/75	Racky et al.	260	45.75 P	
	AB	4,036,811	7/19/77	Noetzel et al.	260	45.75 W	
	AC	4,853,424	8/1/89	Staendeke et al.	523	506	
	AD	5,312,853	5/17/94	Staendeke et al.	524	100	
	AE	5,326,805	7/5/94	Sicken et al.	524	101	
	AF	6,207,736	3/27/01	Nass et al.	524	126	
	AG	6,251,961	6/26/01	Pirig et al.	521	179	
	AH	6,255,371	7/3/01	Schlosser et al.	521	100	
	AI	6,344,158	2/5/02	Schlosser et al.	252	609	
	AJ	6,365,071	4/2/02	Jenewein et al.	252	609	
	AK	6,380,273	4/30/02	Eilbrach et al.	521	108	
	AL	6,420,459	7/16/02	Horold	523	451	
	AM	6,509,401	1/21/03	Jenewein et al.	524	116	
	AN	6,547,992	4/15/03	Schlosser et al.	252	609	
	AO	6,548,627	4/15/03	Horold	528	398	
	AP	6,617,382	9/9/03	Pirig et al.	524	115	
	AQ	6,639,017	10/28/03	Horold et al.	525	168	
	AR	6,642,284	11/4/03	Thewes et al	521	146	
EXAMINER				DATE CONSIDERED			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							